Geburtshilfe Frauenheilkd 2018; 78(10): 252
DOI: 10.1055/s-0038-1671524
Poster
Freitag, 02.11.2018
Senologie III
Georg Thieme Verlag KG Stuttgart · New York

PGRMC1 promotes tumour progression of breast cancer by upregulating of ERα expression and EGFR signalling

M Willibald
1  Universitätsklinikum Düsseldorf, Klinik für Frauenheilkunde und Geburtshilfe, Düsseldorf, Deutschland
,
V Stahlhut
1  Universitätsklinikum Düsseldorf, Klinik für Frauenheilkunde und Geburtshilfe, Düsseldorf, Deutschland
,
N Kessler
1  Universitätsklinikum Düsseldorf, Klinik für Frauenheilkunde und Geburtshilfe, Düsseldorf, Deutschland
,
N Stamm
1  Universitätsklinikum Düsseldorf, Klinik für Frauenheilkunde und Geburtshilfe, Düsseldorf, Deutschland
,
B Gierke
2  NMI Natural and Medical Science Institute, Universität Tübingen, Reutlingen, Deutschland
,
M Pawlak
2  NMI Natural and Medical Science Institute, Universität Tübingen, Reutlingen, Deutschland
,
T Fehm
1  Universitätsklinikum Düsseldorf, Klinik für Frauenheilkunde und Geburtshilfe, Düsseldorf, Deutschland
,
H Neubauer
1  Universitätsklinikum Düsseldorf, Klinik für Frauenheilkunde und Geburtshilfe, Düsseldorf, Deutschland
› Author Affiliations
Further Information

Publication History

Publication Date:
20 September 2018 (online)

 

The hormone receptor progesterone receptor membrane component-1 (PGRMC1) is upregulated in breast cancer and elevated expression of PGRMC1 is associated with increased tumour growth and poorer outcome, indicating a contribution of PGRMC1 in carcinogenesis of breast cancer. However, the role of PGRMC1 in breast cancer, its activation mechanism and involved signalling pathways are not fully understood yet. Therefore, the aim of the present study was to investigate the role of PGRMC1 in breast cancer progression, the last step of carcinogenesis.

Expression of PGRMC1 in breast cancer subtypes was investigated using TCGA data and correlated with overall- and metastasis free survival. The effect of PGRMC1 overexpression and -knockdown on proliferation was examined in vitro and in a xenograft model. Since the function of PGRMC1 is suggested to be regulated by differential phosphorylation, the PGRMC1 phosphorylation-status and the significance of PGRMC1 phosphorylation on cell proliferation was investigated. With the aim to further elucidate PGRMC1 signalling in breast cancer, we searched for signalling pathways which might be regulated by PGRMC1.

Expression of PGRMC1 was observed in every breast cancer subtype and high expression of PGRMC1 correlated with poorer outcome. Overexpression of PGRMC1 in the hormone-receptor positive cell lines MCF7 and T47D resulted in significant enhanced proliferation. Analysis of PGRMC1-dependent expression and activation of proteins revealed upregulation of ERα and ERα-dependent genes, as well as activation of EGFR signalling cascade. PGRMC1 phosphorylation at S56 and S181 was identified to be essential for enhanced proliferation and upregulation of ERα and ERα-dependent genes.

Our results emphasize an important role of PGRMC1 in breast cancer progression and display a potential embedding of PGRMC1 in important breast cancer signalling pathways. PGRMC1 might therefore be an interesting target for anti-cancer therapy.